Barclays Portfolio holdings
Barclays is a British universal bank whose roots go back to 1690, when the Quakers John Freame and Thomas Gould started a goldsmith banking business in London. The Barclays name came into the business in 1736, when James Barclay, son-in-law of founder John Freame, became a partner. Barclays launched the UK's first credit card, Barclaycard, in 1966, and in 1967 put the world's first cash machine in a branch in Enfield. In 2008 Barclays bought the North American operations of Lehman Brothers, and in 2009 it sold its Barclays Global Investors unit, home of the iShares ETFs, to BlackRock. It runs five divisions: UK consumer banking, UK corporate banking, private banking and wealth management, an investment bank and a US consumer bank.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tesla
TSLA
|
+$17.5B |
| 2 |
NVIDIA
NVDA
|
+$2.7B |
| 3 |
Intel
INTC
|
+$1.98B |
| 4 |
Broadcom
AVGO
|
+$1.46B |
| 5 |
iShares iBoxx $ High Yield Corporate Bond ETF
HYG
|
+$1.11B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares MSCI Emerging Markets ETF
EEM
|
+$35.8B |
| 2 |
Apple
AAPL
|
+$1.83B |
| 3 |
Invesco QQQ Trust
QQQ
|
+$913M |
| 4 |
Microsoft
MSFT
|
+$856M |
| 5 |
Bank of America
BAC
|
+$792M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 49.47% |
| 2 | Technology | 19.84% |
| 3 | Consumer Discretionary | 7.61% |
| 4 | Financials | 5.61% |
| 5 | Communication Services | 3.94% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
5051
Edesa Biotech
EDSA
$20.6M
| $17 | ﹤0.01% |
+4
| New | +$21 |
2026 Q3
0 quarters
|
|
5052
Fortress Biotech
FBIO
$61.7M
| $17 | ﹤0.01% |
8
-986
| -99% | -$2.83K |
2026 Q2
1 quarter
|
|
5053
NeOnc Technologies
NTHI
$101M
| $17 | ﹤0.01% |
5
-448
| -99% | -$1.75K |
2025 Q3
4 quarters
|
|
5054
Canterbury Park Holding Corp
CPHC
$81.5M
| $16 | ﹤0.01% |
1
-6
| -86% | -$94 |
2026 Q2
1 quarter
|
|
5055
Lite Strategy Inc
LITS
$31.5M
| $16 | ﹤0.01% |
12
-520
| -98% | -$538 |
2026 Q2
1 quarter
|
|
5056
Coya Therapeutics
COYA
$70.1M
| $15 | ﹤0.01% |
3
-110
| -97% | -$524 |
2026 Q2
1 quarter
|
|
5057
Champions Oncology
CSBR
$66.7M
| $15 | ﹤0.01% |
3
-10
| -77% | -$53 |
2026 Q2
1 quarter
|
|
5058
Data I/O
DAIO
$24.4M
| $15 | ﹤0.01% |
5
-45
| -90% | -$137 |
2026 Q2
1 quarter
|
|
5059
DLH Holdings
DLHC
$52.3M
| $15 | ﹤0.01% |
4
-46
| -92% | -$211 |
2026 Q2
1 quarter
|
|
5060
Geospace Technologies
GEOS
$49M
| $15 | ﹤0.01% |
+3
| New | +$18 |
2026 Q3
0 quarters
|
|
5061
Live Ventures
LIVE
$22M
| $15 | ﹤0.01% |
2
-7
| -78% | -$66 |
2026 Q2
1 quarter
|
|
5062
Alset
AEI
$19.1M
| $14 | ﹤0.01% |
19
-67
| -78% | -$80 |
2026 Q2
1 quarter
|
|
5063
Laird Superfood
LSF
$24.8M
| $14 | ﹤0.01% |
4
-105
| -96% | -$433 |
2026 Q2
1 quarter
|
|
5064
DELISTED
NSTS Bancorp
NSTS
| $14 | ﹤0.01% |
1
-5
| -83% | -$70 |
2026 Q2
1 quarter
|
|
5065
Spruce Power Holding Corp
SPRU
$31.4M
| $14 | ﹤0.01% |
8
-88
| -92% | -$179 |
2026 Q2
1 quarter
|
|
5066
Instil Bio
TIL
$46.3M
| $14 | ﹤0.01% |
2
-27
| -93% | -$200 |
2024 Q1
10 quarters
|
|
5067
United-Guardian
UG
$30.8M
| $14 | ﹤0.01% |
2
| – | – |
2026 Q2
1 quarter
|
|
5068
Vivani Medical
VANI
$96.5M
| $14 | ﹤0.01% |
11
-652
| -98% | -$876 |
2026 Q2
1 quarter
|
|
5069
Caring Brands
CABR
$10.7M
| $14 | ﹤0.01% |
+11
| New | +$15 |
2026 Q3
0 quarters
|
|
5070
Air Industries Group
AIRI
$13.6M
| $13 | ﹤0.01% |
5
-54
| -92% | -$143 |
2026 Q2
1 quarter
|
|
5071
Fluent
FLNT
$121M
| $13 | ﹤0.01% |
+4
| New | +$14 |
2026 Q3
0 quarters
|
|
5072
Seres Therapeutics
MCRB
$20.2M
| $13 | ﹤0.01% |
4
-163
| -98% | -$822 |
2025 Q3
4 quarters
|
|
5073
Usio Inc
USIO
$84.3M
| $13 | ﹤0.01% |
5
-153
| -97% | -$367 |
2026 Q2
1 quarter
|
|
5074
Xos
XOS
$34.5M
| $13 | ﹤0.01% |
+4
| New | +$11 |
2026 Q3
0 quarters
|
|
5075
Cardlytics
CDLX
$11.5M
| $12 | ﹤0.01% |
4
-127
| -97% | -$500 |
2019 Q1
30 quarters
|
|
Similar funds
Barclays's Q3 2026 Portfolio in Review
As of Q3 2026, Barclays held 5,855 positions worth $500B, down 4% from $521B the previous quarter. Its ten largest holdings account for 40% of the portfolio.
Barclays withdrew a net $19B in Q3 2026, closing 474 positions and reducing 1,494 holdings. Its most notable exit was ExxonMobil, an estimated $761M position sold in full.
By sector, the portfolio is most concentrated in Miscellaneous at 49% of assets, down from 55% a quarter earlier, followed by Technology and Consumer Discretionary.
Against the trend, Barclays opened a new position in iShares Broad USD High Yield Corporate Bond ETF worth $199M.
- Barclays's largest Q3 2026 buy was iShares Broad USD High Yield Corporate Bond ETF: 5,582,517 shares worth $199M.
- Barclays added most to Tesla in Q3 2026, an estimated $17.5B increase.
- Barclays's biggest Q3 2026 reduction was iShares MSCI Emerging Markets ETF, cutting an estimated $35.8B.
- Barclays fully exited ExxonMobil in Q3 2026, selling an estimated $761M.
- Barclays's ten largest holdings make up 40% of its $500B portfolio in Q3 2026.
- Barclays opened 525 new positions and closed 474 in Q3 2026.
- Barclays's portfolio value fell 4% quarter-over-quarter to $500B.
Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.